10-KPeriod: FY2001

BIOGEN INC. Annual Report, Year Ended Dec 31, 2001

Filed April 1, 2002For Securities:BIIB

Summary

IDEC Pharmaceuticals Corporation, now known as Biogen Inc., reported strong revenue growth driven by its flagship product, Rituxan, which saw an 84% increase in U.S. net sales in 2001, reaching $779.0 million. This performance underscores Rituxan's significant market acceptance and its role as a leading therapy for B-cell non-Hodgkin's lymphomas (NHL). The company also achieved a major milestone with the FDA approval of its second product, ZEVALIN, in February 2002, positioning it as a complementary radioimmunotherapy for certain B-cell NHLs. IDEC's robust financial position, with $866.6 million in cash, cash equivalents, and securities available-for-sale as of December 31, 2001, supports its ongoing investment in a promising pipeline of autoimmune and inflammatory disease candidates, including IDEC-131, IDEC-114, IDEC-151, and IDEC-152, which are in various stages of clinical development. The company's strategic partnerships with Genentech, Roche, and Schering AG are crucial to its commercialization efforts for Rituxan and ZEVALIN, respectively. While Rituxan's manufacturing is handled by Genentech, IDEC is scaling up its own manufacturing capabilities for future products. Despite ongoing legal challenges concerning intellectual property, particularly related to Rituxan and ZEVALIN, IDEC Pharmaceuticals appears financially sound and well-positioned to navigate the competitive biopharmaceutical landscape.

Key Highlights

  • 1Strong revenue growth driven by Rituxan, with U.S. net sales increasing 84% to $779.0 million in 2001.
  • 2FDA approval of ZEVALIN in February 2002, expanding the company's product portfolio in B-cell NHL treatment.
  • 3Significant cash reserves of $866.6 million as of December 31, 2001, enabling continued investment in R&D and pipeline expansion.
  • 4Active development of multiple product candidates for autoimmune and inflammatory diseases (IDEC-131, IDEC-114, IDEC-151, IDEC-152) in various clinical trial phases.
  • 5Strategic partnerships with major pharmaceutical companies like Genentech, Roche, and Schering AG for commercialization and global reach.
  • 6Ongoing legal proceedings related to intellectual property for key products, which could impact future sales and profitability.
  • 7Increased R&D and SG&A expenses, reflecting investment in product development, clinical trials, and commercialization efforts for ZEVALIN.

Frequently Asked Questions

IDEC Pharmaceuticals' primary commercial products are Rituxan® and ZEVALIN™. Rituxan® is a monoclonal antibody for treating B-cell non-Hodgkin's lymphomas (NHL), and its U.S. net sales grew significantly by 84% to $779.0 million in 2001. ZEVALIN™, a radioimmunotherapy for certain B-cell NHLs, received FDA approval in February 2002, marking a significant expansion for the company.

As of December 31, 2001, IDEC Pharmaceuticals had strong liquidity with $866.6 million in cash, cash equivalents, and securities available-for-sale. Its revenues are primarily driven by Rituxan sales through a copromotion agreement with Genentech, supplemented by license fees and contract revenues from collaborations. The company has positive retained earnings, indicating a solid financial position to fund ongoing research and development.

Key risks include the substantial reliance on Rituxan sales for revenue, potential challenges in the commercialization of ZEVALIN, uncertainties in clinical trial outcomes for pipeline candidates, reliance on contract manufacturers and suppliers, and intense competition in the biopharmaceutical industry. The company is also involved in patent litigation concerning its core products, which could adversely affect its business.